Skip to main navigation

News
Alerts
Careers
Contact

About
Pipeline
Rezafungin
Cloudbreak™
- Overview
- ADC
Publications
Investors
Secondary Investor Relations

Press enter to begin your search

Home
About
Drug Candidates
- Pipeline
- CD101 IV
- CD101 Topical
- C001
- Publications
Cloudbreak™
Opportunity
Investors
Secondary Investor Relations
Contact

Event Calendar

Event Calendar

UPCOMING EVENTS

More events are coming soon.

NAVIGATION

Overview
Financials
- SEC Filings
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tool Kit

	Print Page
	RSS Feeds
	E-mail Alerts

Get Important News and Updates by Email Subscribe

About Cidara

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives and immunotherapies that have the potential to transform the standard of care and save or improve patients' lives.
Learn more >>

Recent News

Cidara Therapeutics to Present New Rezafungin Data at the 2018 Hot Topics in Infectious Diseases Conference

October 15, 2018

Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018

October 4, 2018

Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections

September 27, 2018

Navigation

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Contact Us

Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Tel: (858) 752-6170
Email: info@cidara.com

© 2018 Cidara Therapeutics, Inc. | Terms of Use | Privacy Policy

Quick Links

Secondary Investor Relations

Overview
Presentations
Financials
Stock Information
Corporate Governance
News & Events
Analyst Coverage
Shareholder Services

Tweets by @CidaraThera